Risk Factors of ICU-acquired Weakness (ICU-AW)
ICU-acquired Weakness in Extracorporeal Membrane Oxygenation Support: Frequency and Risk Factors
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: xinyi chen, master
- Phone Number: 19858875700
- Email: chenxinyi0323@zju.edu.cn
Study Locations
-
-
Please Select
-
Hangzhou, Please Select, China, 310000
- Recruiting
- Xinyi Chen
-
Contact:
- xinyi chen
- Phone Number: 19858875700
- Email: chenxinyi0323@zju.edu.cn
-
Contact:
- man huang
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Critical ill patients who used extracorporeal membrane oxygenation during their ICU stay. Patients were recruited from the general ICU of the second affiliated hospital of Zhejiang University, between March 2017 to March 2020.
Exclusion Criteria:
- Patients who was less than 18 years old, had been proven or suspected neurological impairment, using extracorporeal membrane oxygenation less than 24 hours, severe head or spinal cord injury and pregnant woman.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
ICU-acquired weakness group
Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60 when discharged.
|
|
no ICU-acquired weakness group
Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences between ICU-acquired weakness in patients receiving extracorporeal membrane oxygenation support
Time Frame: 1 day
|
We compared the clinical characteristics between ICU-acquired weakness group and no ICU-acquired weakness group by univariate analysis .
Then we used logistic regression analysis and found out differences of ICU-acquired weakness.
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of ICU-acquired weakness in in patients receiving extracorporeal membrane oxygenation support
Time Frame: 1 day
|
We calculated the prevalence of ICU-acquired weakness on the patients included in our research.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-0041 (Other Identifier: M D Anderson Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.